Corvus Pharmaceuticals (NASDAQ:CRVS) Price Target Lowered to $11.00 at Mizuho

Corvus Pharmaceuticals (NASDAQ:CRVS) had its price target lowered by Mizuho from $12.00 to $11.00 in a research note published on Tuesday,Benzinga reports. Mizuho currently has an outperform rating on the stock.

Other analysts have also issued reports about the company. HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of Corvus Pharmaceuticals in a research report on Wednesday, March 26th. Oppenheimer restated an “outperform” rating and set a $17.00 price objective (up previously from $15.00) on shares of Corvus Pharmaceuticals in a research note on Friday, May 9th. Finally, StockNews.com raised shares of Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, May 12th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $15.00.

Corvus Pharmaceuticals Trading Up 1.7%

NASDAQ CRVS opened at $3.68 on Tuesday. The stock has a market cap of $250.86 million, a P/E ratio of -3.96 and a beta of 0.67. The company’s fifty day simple moving average is $3.52 and its 200-day simple moving average is $5.24. Corvus Pharmaceuticals has a 52 week low of $1.75 and a 52 week high of $10.00.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.13). On average, research analysts expect that Corvus Pharmaceuticals will post -0.63 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Virtus ETF Advisers LLC acquired a new stake in shares of Corvus Pharmaceuticals during the 4th quarter valued at approximately $47,000. PKS Advisory Services LLC acquired a new position in Corvus Pharmaceuticals in the fourth quarter worth $56,000. Alpine Global Management LLC bought a new stake in Corvus Pharmaceuticals during the fourth quarter valued at $62,000. Sowell Financial Services LLC acquired a new stake in shares of Corvus Pharmaceuticals during the first quarter worth $38,000. Finally, ExodusPoint Capital Management LP acquired a new stake in shares of Corvus Pharmaceuticals during the fourth quarter worth $72,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.